drugset / Trial / NCT02191579

Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults

NCT02191579

Phase 4 Completed 282 enrolled Allergan
RandomizedParallel-groupOpen-labelPrevention

Summary

This study will evaluate the efficacy, safety and tolerability of prophylactic (preventative) treatment with BOTOX® (onabotulinumtoxinA) compared to topiramate in adults with chronic migraine.

Timeline

Start
2014-08-05
Primary completion
2017-05-09
Completion
2017-09-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 155 iu Intramuscular
Comparator Topiramate Small molecule 100 mg Oral

Indications